1134 studies found for:    Open Studies | "Neuroectodermal Tumors"
Show Display Options
Rank Status Study
1 Recruiting Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Conditions: Adult Supratentorial Primitive Neuroectodermal Tumor (PNET);   Childhood Supratentorial Primitive Neuroectodermal Tumor;   Ewing Sarcoma of Bone;   Extraosseous Ewing Sarcoma;   Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Peripheral Primitive Neuroectodermal Tumor of the Kidney;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: ifosfamide;   Drug: etoposide;   Drug: topotecan hydrochloride;   Other: laboratory biomarker analysis
2 Recruiting Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma
Conditions: Adult Supratentorial Primitive Neuroectodermal Tumor (PNET);   Ewing Sarcoma of Bone;   Extraosseous Ewing Sarcoma;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: etoposide;   Drug: ifosfamide;   Radiation: intensity-modulated radiation therapy;   Drug: topotecan hydrochloride;   Drug: busulfan;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: autologous bone marrow transplantation
3 Recruiting Collecting and Storing Biological Samples From Patients With Ewing Sarcoma
Conditions: Askin Tumor;   Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Intervention: Other: laboratory biomarker analysis
4 Recruiting Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
Conditions: Acoustic Schwannoma;   Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Meningioma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Choroid Plexus Tumor;   Adult Craniopharyngioma;   Adult Diffuse Astrocytoma;   Adult Ependymoblastoma;   Adult Ependymoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Grade I Meningioma;   Adult Grade II Meningioma;   Adult Medulloblastoma;   Adult Meningeal Hemangiopericytoma;   Adult Mixed Glioma;   Adult Myxopapillary Ependymoma;   Adult Oligodendroglioma;   Adult Papillary Meningioma;   Adult Pilocytic Astrocytoma;   Adult Pineal Gland Astrocytoma;   Adult Pineoblastoma;   Adult Pineocytoma;   Adult Subependymal Giant Cell Astrocytoma;   Adult Subependymoma;   Adult Supratentorial Primitive Neuroectodermal Tumor (PNET);   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Ependymoblastoma;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood High-grade Cerebellar Astrocytoma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Infratentorial Ependymoma;   Childhood Low-grade Cerebellar Astrocytoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Medulloepithelioma;   Childhood Supratentorial Ependymoma;   Meningeal Melanocytoma;   Newly Diagnosed Childhood Ependymoma;   Recurrent Adult Brain Tumor;   Recurrent Childhood Anaplastic Astrocytoma;   Recurrent Childhood Anaplastic Oligoastrocytoma;   Recurrent Childhood Anaplastic Oligodendroglioma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Diffuse Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Fibrillary Astrocytoma;   Recurrent Childhood Gemistocytic Astrocytoma;   Recurrent Childhood Giant Cell Glioblastoma;   Recurrent Childhood Glioblastoma;   Recurrent Childhood Gliomatosis Cerebri;   Recurrent Childhood Gliosarcoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Oligoastrocytoma;   Recurrent Childhood Oligodendroglioma;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Pilomyxoid Astrocytoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Pleomorphic Xanthoastrocytoma;   Recurrent Childhood Protoplasmic Astrocytoma;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Untreated Childhood Anaplastic Astrocytoma;   Untreated Childhood Anaplastic Oligodendroglioma;   Untreated Childhood Brain Stem Glioma;   Untreated Childhood Cerebellar Astrocytoma;   Untreated Childhood Cerebral Astrocytoma;   Untreated Childhood Diffuse Astrocytoma;   Untreated Childhood Fibrillary Astrocytoma;   Untreated Childhood Gemistocytic Astrocytoma;   Untreated Childhood Giant Cell Glioblastoma;   Untreated Childhood Glioblastoma;   Untreated Childhood Gliomatosis Cerebri;   Untreated Childhood Gliosarcoma;   Untreated Childhood Medulloblastoma;   Untreated Childhood Oligoastrocytoma;   Untreated Childhood Oligodendroglioma;   Untreated Childhood Pilocytic Astrocytoma;   Untreated Childhood Pilomyxoid Astrocytoma;   Untreated Childhood Pineoblastoma;   Untreated Childhood Pleomorphic Xanthoastrocytoma;   Untreated Childhood Protoplasmic Astrocytoma;   Untreated Childhood Subependymal Giant Cell Astrocytoma;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor;   Untreated Childhood Visual Pathway and Hypothalamic Glioma;   Untreated Childhood Visual Pathway Glioma
Interventions: Radiation: gallium Ga 68-edotreotide;   Procedure: positron emission tomography;   Procedure: computed tomography;   Other: laboratory biomarker analysis
5 Recruiting Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
Conditions: Medulloblastoma;   Neuroectodermal Tumor
Interventions: Biological: TTRNA-xALT;   Biological: TTRNA-DCs
6 Recruiting Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
Conditions: Desmoplastic Small Round Cell Tumor;   Ewing Sarcoma of Bone or Soft Tissue;   Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Interventions: Drug: vincristine;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: ifosfamide;   Drug: etoposide;   Drug: temozolomide;   Drug: temsirolimus;   Drug: bevacizumab;   Drug: sorafenib;   Procedure: surgery;   Radiation: radiation
7 Recruiting Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Conditions: Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Desmoplastic Small Round Cell Tumor;   Adult Epithelioid Hemangioendothelioma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Malignant Mesenchymoma;   Adult Neurofibrosarcoma;   Adult Rhabdomyosarcoma;   Adult Synovial Sarcoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Dermatofibrosarcoma Protuberans;   Gastrointestinal Stromal Tumor;   Metastatic Adult Malignant Fibrous Histiocytoma of Bone;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Osteosarcoma;   Ovarian Sarcoma;   Recurrent Adult Malignant Fibrous Histiocytoma of Bone;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Kaposi Sarcoma;   Recurrent Osteosarcoma;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage III Uterine Sarcoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Uterine Sarcoma
Interventions: Drug: vismodegib;   Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis;   Other: pharmacological study
8 Recruiting Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot be Removed by Surgery or Are Metastatic
Conditions: Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Endometrial Stromal Sarcoma;   Ewing Sarcoma of Bone;   Extraosseous Ewing Sarcoma;   Gastrointestinal Stromal Tumor;   Mast Cell Sarcoma;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Osteosarcoma;   Ovarian Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Osteosarcoma;   Recurrent Uterine Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage III Uterine Sarcoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Uterine Sarcoma
Interventions: Drug: dasatinib;   Biological: ipilimumab;   Other: laboratory biomarker analysis;   Other: pharmacological study
9 Recruiting 18F-DOPA-PET in Planning Surgery in Patients With Gliomas
Conditions: Acoustic Schwannoma;   Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Meningioma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Choroid Plexus Tumor;   Adult Craniopharyngioma;   Adult Diffuse Astrocytoma;   Adult Ependymoblastoma;   Adult Ependymoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Grade I Meningioma;   Adult Grade II Meningioma;   Adult Medulloblastoma;   Adult Meningeal Hemangiopericytoma;   Adult Mixed Glioma;   Adult Myxopapillary Ependymoma;   Adult Oligodendroglioma;   Adult Papillary Meningioma;   Adult Pilocytic Astrocytoma;   Adult Pineal Gland Astrocytoma;   Adult Pineoblastoma;   Adult Pineocytoma;   Adult Subependymal Giant Cell Astrocytoma;   Adult Subependymoma;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Ependymoblastoma;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood High-grade Cerebellar Astrocytoma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Infratentorial Ependymoma;   Childhood Low-grade Cerebellar Astrocytoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Medulloepithelioma;   Childhood Mixed Glioma;   Childhood Supratentorial Ependymoma;   Meningeal Melanocytoma;   Newly Diagnosed Childhood Ependymoma;   Recurrent Adult Brain Tumor;   Recurrent Childhood Anaplastic Astrocytoma;   Recurrent Childhood Anaplastic Oligoastrocytoma;   Recurrent Childhood Anaplastic Oligodendroglioma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Diffuse Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Fibrillary Astrocytoma;   Recurrent Childhood Gemistocytic Astrocytoma;   Recurrent Childhood Giant Cell Glioblastoma;   Recurrent Childhood Glioblastoma;   Recurrent Childhood Gliomatosis Cerebri;   Recurrent Childhood Gliosarcoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Oligoastrocytoma;   Recurrent Childhood Oligodendroglioma;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Pilomyxoid Astrocytoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Pleomorphic Xanthoastrocytoma;   Recurrent Childhood Protoplasmic Astrocytoma;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Untreated Childhood Anaplastic Astrocytoma;   Untreated Childhood Anaplastic Oligoastrocytoma;   Untreated Childhood Anaplastic Oligodendroglioma;   Untreated Childhood Brain Stem Glioma;   Untreated Childhood Diffuse Astrocytoma;   Untreated Childhood Fibrillary Astrocytoma;   Untreated Childhood Gemistocytic Astrocytoma;   Untreated Childhood Giant Cell Glioblastoma;   Untreated Childhood Glioblastoma;   Untreated Childhood Gliomatosis Cerebri;   Untreated Childhood Gliosarcoma;   Untreated Childhood Medulloblastoma;   Untreated Childhood Oligoastrocytoma;   Untreated Childhood Oligodendroglioma;   Untreated Childhood Pilocytic Astrocytoma;   Untreated Childhood Pilomyxoid Astrocytoma;   Untreated Childhood Pineoblastoma;   Untreated Childhood Pleomorphic Xanthoastrocytoma;   Untreated Childhood Protoplasmic Astrocytoma;   Untreated Childhood Subependymal Giant Cell Astrocytoma;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor;   Untreated Childhood Visual Pathway and Hypothalamic Glioma;   Untreated Childhood Visual Pathway Glioma
Interventions: Drug: fluorine F 18 fluorodopa;   Procedure: positron emission tomography;   Procedure: computed tomography;   Procedure: diffusion-weighted magnetic resonance imaging;   Procedure: perfusion-weighted magnetic resonance imaging;   Procedure: therapeutic conventional surgery;   Procedure: biopsy;   Other: laboratory biomarker analysis
10 Unknown  Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years
Condition: Metastatic, Cerebral Primitive Neuroectodermal Tumors
Intervention: Drug: Chemotherapy (carboplatin, etoposide, thiotepa)
11 Recruiting Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
Conditions: Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: temozolomide;   Drug: irinotecan hydrochloride;   Biological: bevacizumab
12 Not yet recruiting Molecular-Guided Therapy for Childhood Cancer
Conditions: Neuroblastoma;   Medulloblastoma;   Glioma;   Ependymoma;   Choroid Plexus Neoplasms;   Craniopharyngioma;   Dysembryoplastic Neuroepithelial Tumor;   Meningioma;   Primitive Neuroectodermal Tumors (PNETs);   Germ Cell Tumors;   Rhabdomyosarcoma;   Non-rhabdomyosarcoma;   Ewings Sarcoma;   Osteosarcoma;   Wilms Tumor;   Renal Cell Carcinoma;   Malignant Rhabdoid Tumor;   Clear Cell Sarcoma;   Liver Tumors
Intervention: Device: Guided Therapy
13 Recruiting WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Conditions: Recurrent Childhood Medulloblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Neuroblastoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: WEE1 inhibitor MK-1775;   Drug: irinotecan hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis
14 Not yet recruiting Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer
Conditions: Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Ependymoblastoma;   Childhood Extracranial Germ Cell Tumor;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood High-grade Cerebellar Astrocytoma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Infratentorial Ependymoma;   Childhood Low-grade Cerebellar Astrocytoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Malignant Ovarian Germ Cell Tumor;   Childhood Malignant Testicular Germ Cell Tumor;   Childhood Medulloepithelioma;   Childhood Supratentorial Ependymoma;   Childhood Teratoma;   Recurrent Childhood Anaplastic Astrocytoma;   Recurrent Childhood Anaplastic Oligoastrocytoma;   Recurrent Childhood Anaplastic Oligodendroglioma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Diffuse Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Fibrillary Astrocytoma;   Recurrent Childhood Gemistocytic Astrocytoma;   Recurrent Childhood Giant Cell Glioblastoma;   Recurrent Childhood Glioblastoma;   Recurrent Childhood Gliomatosis Cerebri;   Recurrent Childhood Gliosarcoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Oligoastrocytoma;   Recurrent Childhood Oligodendroglioma;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Pilomyxoid Astrocytoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Pleomorphic Xanthoastrocytoma;   Recurrent Childhood Protoplasmic Astrocytoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Retinoblastoma;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: etoposide;   Drug: ifosfamide;   Drug: carboplatin;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate;   Drug: cyclophosphamide;   Drug: cisplatin;   Biological: filgrastim;   Other: laboratory biomarker analysis
15 Recruiting Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors
Conditions: Glioma;   Neuroectodermal Tumors, Primitive;   Wilms Tumor;   Rhabdomyosarcoma;   Sarcoma, Ewing;   Osteosarcoma;   Retinoblastoma
Interventions: Drug: Metronomic Cyclophosphamide;   Drug: Thalidomide
16 Not yet recruiting NAC to Prevent Cisplatin-induced Hearing Loss
Conditions: Neuroectodermal Tumors, Primitive;   Liver Neoplasms;   Neoplasms, Germ Cell and Embryonal;   Osteosarcoma;   Other Childhood Cancers Using Cisplatin-based Regimens
Intervention: Drug: N-Acetylcysteine
17 Unknown  High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood
Conditions: Medulloblastoma;   Brain Tumors;   Neuroectodermal Tumors, Primitive
Intervention: Drug: Etoposide, carboplatin, melphalan, cisplatin, thiotepa
18 Recruiting Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients
Conditions: Glioblastoma;   Nervous System Neoplasms;   Central Nervous System Neoplasms;   Astrocytoma;   Glioma;   Neoplasms, Neuroepithelial;   Neuroectodermal Tumors;   Neoplasms by Histologic Type;   Neoplasms, Nerve Tissue
Intervention:
19 Unknown  Establishment of a Brain and Spinal Tumor Tissue Bank
Conditions: Glioblastoma Multiforme;   Glioma;   Neuroectodermal Tumors
Intervention:
20 Recruiting Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Primary Hepatocellular Carcinoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Hormone-resistant Prostate Cancer;   Limited Stage Small Cell Lung Cancer;   Localized Resectable Adult Primary Liver Cancer;   Male Breast Cancer;   Mast Cell Sarcoma;   Ovarian Sarcoma;   Recurrent Adult Brain Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esophageal Cancer;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Gastric Cancer;   Recurrent Kaposi Sarcoma;   Recurrent Melanoma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Osteosarcoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage I Colon Cancer;   Stage I Rectal Cancer;   Stage I Uterine Sarcoma;   Stage IA Breast Cancer;   Stage IA Gastric Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IB Breast Cancer;   Stage IB Gastric Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IC Ovarian Epithelial Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage II Breast Cancer;   Stage II Uterine Sarcoma;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Gastric Cancer;   Stage IIB Melanoma;   Stage IIB Non-small Cell Lung Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Melanoma;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Melanoma;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Melanoma;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IV Bladder Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Uterine Sarcoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: DEC-205-NY-ESO-1 fusion protein vaccine;   Drug: sirolimus;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years